International Journal of Chronic Obstructive Pulmonary Disease最新文献

{"title":"Factors Associated with Exertional Desaturation in Patients with Chronic Obstructive Pulmonary Disease.","authors":"Seungju Kim, Chin Kook Rhee, Chang Youl Lee, Deog Kyeom Kim, Soo-Jung Um, Seong Yong Lim, Yong Bum Park, Hyoung Kyu Yoon, Kwang Ha Yoo, Won-Yeon Lee","doi":"10.2147/COPD.S522341","DOIUrl":"10.2147/COPD.S522341","url":null,"abstract":"<p><p>The six minute walk test (6MWT) has a prognostic role in patients with chronic obstructive pulmonary disease (COPD). The aim of this study was to determine the factors associated with desaturation during the 6MWT in patients with COPD. This study utilized data from the prospective KOrea COPD Subgroup Study (KOCOSS) cohort. The results of the 6MWT performed at enrollment were analyzed in this study. A total of 1789 participants performed the 6MWT. Among them, 185 (10.3%) experienced desaturation during 6MWT. Old age, ex-smoker, low forced expiratory volume in one second (%), and high COPD assessment test score were significantly associated with exertional desaturation.</p>","PeriodicalId":48818,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"20 ","pages":"2847-2852"},"PeriodicalIF":3.1,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12358123/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144876317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nonlinear Association Between Weekday Sleep Duration and COPD Risk: Evidence From NHANES 2017-2023.","authors":"Xinxin Tao, Xianwei Ye","doi":"10.2147/COPD.S522236","DOIUrl":"10.2147/COPD.S522236","url":null,"abstract":"<p><strong>Background: </strong>Chronic Obstructive Pulmonary Disease (COPD) is a major global health concern. Lifestyle factors play a pivotal role in its prevention. This research aims to explore the possible link between Weekday Sleep Duration (WSD) and the prevalence of COPD within the US population.</p><p><strong>Methods: </strong>We employed data sourced from the NHANES during the 2017-2023 cycles. The research was centered around COPD. The primary exposure variable, WSD, was grouped by quartiles. Missing values were addressed using multiple imputation. Covariates related to WSD and COPD were pre-identified via a Directed Acyclic Graph (DAG), and highly collinear variables were removed using the Variance Inflation Factor (VIF). Least Absolute Shrinkage and Selection Operator (LASSO) regression further screened variables. Weighted logistic regression was employed to analyze the association between WSD and COPD. Sensitivity analysis tests the stability and reliability of results. Nonlinear relationships were evaluated using Restricted Cubic Splines (RCS) and threshold analysis, while subgroup analyses were performed to assess heterogeneity and validate results. Model performance was gauged by the Area Under the Receiver Operating Characteristic Curve (AUC).</p><p><strong>Results: </strong>After adjusting for all covariates in the weighted logistic regression analysis, we found that higher WSD was consistently correlated with increased prevalence of COPD (P=0.012; OR=1.740; 95% CI, 1.196-2.530). The sensitivity analysis confirms the reliability of our results. The RCS and threshold analysis results show a positive correlation between COPD and WSD (7.0-14.0 hours) (P=0.011; OR=1.12; 95% CI, 1.03-1.22). Subgroup analysis shows that among weekend catch-up sleep (P=0.000), there is a significant positive association between WSD and COPD prevalence. The ROC (AUC=0.811) results show that our model has good diagnostic performance.</p><p><strong>Conclusion: </strong>WSD of 8.5-14 hours/day is associated with higher COPD risk. Prospective studies are needed to validate this novel insight for COPD prevention and treatment.</p>","PeriodicalId":48818,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"20 ","pages":"2823-2836"},"PeriodicalIF":3.1,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12357563/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144876318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alpha-1 Antitrypsin Genotype Distribution in Patients with Emphysema.","authors":"Levent Özdemir, Savaş Gegin, Burcu Özdemir, Esra Arslan Aksu, Ahmet Cemal Pazarlı","doi":"10.2147/COPD.S531347","DOIUrl":"10.2147/COPD.S531347","url":null,"abstract":"<p><strong>Purpose: </strong>Alpha-1 antitrypsin deficiency (AATD) is a rare inherited condition characterized by low serum levels of alpha-1 antitrypsin (AAT). In this study, we aimed to determine the frequency of AATD in patients with emphysema, to show the distribution of AATD genotypes according to the type and localization of emphysema, and to evaluate patients in terms of augmentation therapy.</p><p><strong>Patients and methods: </strong>This cross-sectional descriptive study included 794 patients with emphysema on high-resolution thoracic tomography (HRCT) between December 2022 and December 2024 at the chest disease clinic of the Samsun Training and Research Hospital. During screening, demographic characteristics (age and sex), smoking status (smoker, ex-smoker, and non-smoker), types of emphysema (centriacinar emphysema, panacinar emphysema, and paraseptal emphysema), and location (upper, middle, and lower lobes) were recorded. Dried blood spot samples collected from the fingertips of patients with emphysema were screened for Alpha-1 Antitrypsin (AAT) genotype deficiency. AAT levels and PFT were evaluated in patients with AATD.</p><p><strong>Results: </strong>In the AAT genotyping results, no mutations were detected in 763 (96%) patients, while AATD mutations were detected in 31 (4%) patients. While AATD was more common in panacinar emphysema, no mutations were detected in paraseptal emphysema. The most common mutations were PI*M/M malton (n=9), PI*M/Z (n=7), PI*M/I (n=4), and PI*M malton/M malton (n=4). AAT level was found to be low in PI*Z/Z (n=3), PI*M malton/M malton (n=4) and PI*Z/M malton (n=1) genotypes (0.20±0.2 g/L). Six patients received augmentation therapy for AATD: three had PI*Z/Z, two had PI*M malton/M malton, and one had the PI*Z/M malton genotype.</p><p><strong>Conclusion: </strong>As a result, analyzing AAT genotypes in patients with emphysema may provide an early diagnosis of AATD, allowing the application of preventive measures and augmentation therapy strategies.</p>","PeriodicalId":48818,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"20 ","pages":"2815-2822"},"PeriodicalIF":3.1,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12356220/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144876316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk Factors for Acute Exacerbation in Patients with COPD Group E in Ningbo: Risk Analysis of Irregular Review, Cardiovascular Complications, and Lung Function Decline.","authors":"Yang Qian, Chao Sun, Liang Zhang, Chenting Cai, Mengqing Sun, Jiaqian Zhang, Jian Huang, Hongying Ma, Lin Tan, Yun Zhao, Shanshan Wang, Dan Lv","doi":"10.2147/COPD.S510906","DOIUrl":"10.2147/COPD.S510906","url":null,"abstract":"<p><strong>Objective: </strong>To understand the high-risk factors for disease progression in patients in the chronic obstructive pulmonary disease (COPD) group E in Ningbo, and to explore the impact of and treatment on the prognosis of these patients.</p><p><strong>Methods: </strong>We retrospectively analyzed the clinical data of 101 COPD patients in terms of general demographics, physical baseline data, lung function, disease treatment, and prognosis and used crosstab analysis and logistic regression analysis to understand the characteristics of the population of patients at high risk of acute exacerbation of COPD (AECOPD) and the associated risk factors.</p><p><strong>Results: </strong>Univariate analysis demonstrated that frequent acute exacerbation (AE) in the COPD group E population was significantly associated with more severe airflow limitation, a lower FEF75%, higher mMRC scores, and irregular disease management (P<0.05). Comorbid cardiovascular disease increased AE risk 4.138-fold (P<0.05). Multivariate analysis confirmed that irregular disease review, cardiovascular comorbidity, and mMRC grades 3-4 were risk factors (P<0.05). Regular review reduced AE risk, while cardiovascular disease and mMRC grades 3-4 increased the risk 8.802-fold and 12.327-fold, respectively.</p><p><strong>Conclusion: </strong>The severity of airflow restriction, instantaneous flow during forced exhalation of 75% of the lung capacity, cardiovascular disease complexity, higher mMRC scores, and irregular participation in intervention treatment were associated with disease deterioration in patients at high risk of AECOPD. Regular participation in standardized intervention management and treatment is a protective factor against worsening events in high-risk patients with AECOPD. These results may reduce medical resource utilization and AE frequency while improving quality of life, thereby informing evidence-based COPD management strategies and optimizing chronic disease care and resource allocation.</p>","PeriodicalId":48818,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"20 ","pages":"2787-2799"},"PeriodicalIF":3.1,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12341826/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144838338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the Causal Relationship Between Saliva Microbiota Abundance and Chronic Obstructive Pulmonary Disease/Idiopathic Pulmonary Fibrosis: A Two-Sample Mendelian Randomization Study.","authors":"Haixia Wei, Chunlan Han, Yongna Song","doi":"10.2147/COPD.S519630","DOIUrl":"10.2147/COPD.S519630","url":null,"abstract":"<p><strong>Background: </strong>Idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD) are progressive lung diseases with overlapping risk factors but distinct pathologies. This study employed bidirectional two-sample Mendelian randomization (MR) to explore potential causal relationships between saliva microbiota abundance and the risk of both diseases.</p><p><strong>Methods: </strong>Saliva microbiota abundance datasets were analyzed for forward and reverse causal associations with both diseases. Of 44 datasets, 43 met the inclusion criteria for instrumental variable selection. MR analyses were performed using inverse variance weighted (IVW), MR-Egger, weighted median, and weighted mode methods. Steiger filtering confirmed directionality. Sensitivity analyses included Cochran's Q, MR-Egger intercept, MR-PRESSO, and leave-one-out to assess heterogeneity, pleiotropy, and the influence of individual variants.</p><p><strong>Results: </strong>In forward MR, higher abundance of species <i>parvula</i> was significantly associated with reduced COPD risk (IVW OR = 0.9546, 95% CI = 0.9224-0.9879, P = 0.0020; adjusted P = 0.019). Nominal inverse associations were observed for Bacilli, <i>Porphyromonas</i>, and <i>Fusobacterium</i> with IPF, though these did not remain significant after multiple testing correction. All key associations passed Steiger directionality tests, with no evidence of horizontal pleiotropy or heterogeneity. In reverse MR, COPD showed a nominal positive association with <i>Periodonticum</i> abundance.</p><p><strong>Conclusion: </strong>This exploratory study suggests potential directional associations between specific salivary microbiota and chronic respiratory diseases. <i>Parvula</i> abundance may be protective against COPD, while Bacilli, <i>Porphyromonas</i>, and <i>Fusobacterium</i> may influence IPF risk. These findings support the salivary microbiome as a potential contributor to respiratory disease pathogenesis and warrant further validation in mechanistic and longitudinal studies.</p>","PeriodicalId":48818,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"20 ","pages":"2801-2813"},"PeriodicalIF":3.1,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12341823/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144838333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Economic Analysis of New Single-Inhaler Triple Therapies in Patients with COPD in the UK.","authors":"Rui Cai, Alan A Martin, Yuchen Ge, Nancy A Risebrough, Katrin Haeussler, Christopher Compton, David M G Halpin, Afisi S Ismaila","doi":"10.2147/COPD.S475748","DOIUrl":"10.2147/COPD.S475748","url":null,"abstract":"<p><strong>Purpose: </strong>Chronic obstructive pulmonary disease (COPD) is associated with a substantial economic burden in the UK. Although previous analyses have compared the cost-effectiveness of single-inhaler triple therapy (SITT) versus dual therapy or multiple-inhaler triple therapy, there are no studies investigating the cost-effectiveness of individual SITTs versus other SITTs. This study assessed the cost-effectiveness of SITT with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus other SITTs for the treatment of COPD from a UK National Health Service perspective.</p><p><strong>Patients and methods: </strong>The validated GALAXY-COPD model was populated with patient baseline characteristics from the IMPACT study and treatment effect data from a network meta-analysis, which compared FF/UMEC/VI with budesonide/glycopyrrolate/formoterol fumarate (BUD/GLY/FOR; both 320 µg and 160 µg dosing; BUD320 and BUD160, respectively) and beclometasone dipropionate/formoterol fumarate/glycopyrrolate (BDP/FOR/GLY). UK healthcare resource unit and drug costs (Great British Pound, 2022) were applied, with costs and outcomes (except life years [LYs]) discounted at 3.5% annually. The base case was probabilistic (5000 iterations) with a lifetime horizon.</p><p><strong>Results: </strong>FF/UMEC/VI provided an additional 0.620 (95% range: 0.255, 1.025) LYs and 0.283 (0.080, 0.501) quality-adjusted LYs (QALYs) with a cost saving of £1620 (£158, £3243) versus BUD320/GLY/FOR, an additional 0.627 (0.261, 1.053) LYs and 0.309 (0.097, 0.533) QALYs at a cost saving of £1721 (£261, £3345) versus BUD160/GLY/FOR, and an additional 0.328 (0.063, 0.654) LYs and 0.230 (0.035, 0.437) QALYs at a cost saving of £1221 (-£541, £2796) versus BDP/FOR/GLY. FF/UMEC/VI was less costly and showed higher QALYs in 98.2%, 98.9%, and 93.6% of simulations versus BUD360/GLY/FOR, BUD160/GLY/FOR, and BDP/FOR/GLY, respectively. At a willingness-to-pay threshold of £20,000 per QALY, the probability of FF/UMEC/VI being cost-effective was 99.9%, 100%, and 99.3% versus BUD320/GLY/FOR, BUD160/GLY/FOR, and BDP/FOR/GLY, respectively.</p><p><strong>Conclusion: </strong>Based on this analysis, FF/UMEC/VI is a dominant (improved outcomes with cost savings) treatment option compared with other SITTs for the treatment of patients with COPD in the UK.</p>","PeriodicalId":48818,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"20 ","pages":"2727-2743"},"PeriodicalIF":3.1,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12338100/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144822990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increased Incidence of Chronic Obstructive Pulmonary Disease in Women Due to Long-Term Passive Smoking.","authors":"Zhenkun Liu, Mingzhi Jiao, Jiling Lv, Qizheng Han","doi":"10.2147/COPD.S534060","DOIUrl":"10.2147/COPD.S534060","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the impact of long-term passive smoking on the pathogenesis of chronic obstructive pulmonary disease (COPD) in women.</p><p><strong>Methods: </strong>We conducted a community-based cross-sectional study involving 2,360 women aged ≥40 years in Jinan, China (October 1, 2022-April 30, 2023). Participants underwent comprehensive assessments including pulmonary function tests (spirometry), hematological analyses, and structured questionnaires evaluating COPD symptoms and passive smoking exposure. Based on exposure history, subjects were stratified into long-term passive smoking (LPS, n = 610) and non-passive smoking (NPS, n = 1,750) cohorts.</p><p><strong>Results: </strong>Comparative analysis revealed significant pulmonary function impairment in the LPS group versus NPS controls: lower FEV1 (2.97±0.61 vs 3.25±0.37 L, p < 0.05), reduced FEV1% predicted (78.20±10.18 vs 81.47±14.69, p < 0.05), decreased FEV1/FVC ratio (83.32±11.20 vs 87.23±10.32%, p < 0.05). Small airway dysfunction was more pronounced in LPS participants, evidenced by: diminished MEF75% (77.58±11.95 vs 86.08±14.02 L/s, p < 0.05), reduced MEF50% (62.76±19.79 vs 89.36±16.78 L/s, p < 0.05), lower MMEF (80.87±12.80 vs 87.46±11.26 L/s, p < 0.05). The LPS group demonstrated: higher prevalence of preserved ratio impaired spirometry (PRISm, 5.74% vs 2.91%); increased annual exacerbation frequency (p < 0.05), elevated systemic inflammatory markers (p < 0.05), greater symptom severity (p < 0.05).</p><p><strong>Conclusion: </strong>Our findings demonstrate that chronic passive smoke exposure constitutes an independent risk factor for COPD development in women, associated with higher disease prevalence, accelerated pulmonary function decline, increased exacerbation frequency and enhanced systemic inflammation.</p>","PeriodicalId":48818,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"20 ","pages":"2745-2752"},"PeriodicalIF":3.1,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12338327/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144822991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Burden of COPD with Type 2 Inflammation in North-West Continental Europe.","authors":"Hanna Sandelowsky, Anders Løkke, Janwillem W H Kocks, Helle Stordrange Grøttum, Per S Bakke, Tuula Vasankari","doi":"10.2147/COPD.S523371","DOIUrl":"10.2147/COPD.S523371","url":null,"abstract":"<p><p>Chronic obstructive pulmonary disease (COPD) is a complex and heterogeneous disease that places a huge burden on patients, health systems and societies. Yet despite this, COPD is often neglected: it is frequently underdiagnosed or misdiagnosed, and since tobacco exposure is a primary risk factor for its development, patients are often stigmatized and marginalized because they are perceived as having a \"self-inflicted\" disease. COPD is primarily understood to be a functional disorder with chronic airway obstruction, yet there are several underlying inflammatory pathways. For most patients with COPD, type 1 (neutrophilic) inflammation is the main such pathway; however, a considerable proportion has type 2 inflammation (associated with elevated eosinophil numbers). COPD with type 2 inflammation may represent a distinct COPD phenotype and a \"treatable trait\". In fact, the response to inhaled corticosteroids (ICS) is linked to blood eosinophil levels: treatment effects begin to increase in patients with blood eosinophil counts ≥100 cells/μL, and most treatment guidelines recommend considering ICS for patients with blood eosinophil counts ≥300 cells/μL. Data on the burden of COPD with type 2 inflammation are limited. COPD with type 2 inflammation may associate with poor outcomes, and higher blood eosinophil counts positively associate with an increased risk of moderate or severe exacerbations. Exacerbations are among the most dangerous aspects of COPD, accelerating disease progression and increasing morbidity and mortality. This review explores the burden of COPD - specifically eosinophilic COPD - across north-western Europe. It aims to provide information relevant to patients, clinicians and policymakers, educating them about type 2 inflammation and its contribution to the disease burden. It has been informed by multiple stakeholders, including patients, and offers practical and achievable recommendations for enhancing the care of all patients with COPD through a better understanding of COPD with type 2 inflammation.</p>","PeriodicalId":48818,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"20 ","pages":"2767-2785"},"PeriodicalIF":3.1,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12338087/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144822993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Experience of Dupilumab Treatment for Patients with COPD - A Single Center Prospective Study.","authors":"Ophir Freund, Omer Meoded, Tala Arnaout, Inbal Friedman Regev, Aviv Kupershmidt, Sharon Enghelberg, Doron Cohn-Schwartz, Liran Levy, Amir Bar-Shai","doi":"10.2147/COPD.S525781","DOIUrl":"10.2147/COPD.S525781","url":null,"abstract":"<p><strong>Purpose: </strong>Dupilumab was recently shown to be effective in patients with chronic obstructive pulmonary disease (COPD) and type 2 inflammation, while real-world data are missing. We aimed to evaluate the experience of COPD patients treated with Dupilumab.</p><p><strong>Patients and methods: </strong>Consecutive patients with COPD treated with Dupilumab were approached and completed a structured interview. Before treatment, all patients had blood eosinophil count ≥300 cells/μL and prior-year exacerbations despite triple inhaler therapy.</p><p><strong>Results: </strong>Twenty-three subjects were included, with median (IQR) treatment of 320 (280-355) days, median age of 75 years, and 52% female. A decrease in mean annualize exacerbation rate was observed from 3.47 at baseline to 1.55 after treatment (55% reduction). Number of severe exacerbations decreased as well (median 1 vs 0 over the same time frame). There was a decrease in the median COPD assessment test scores (median of 18 vs 15), although FEV1 did not change. One patient had skin-related side effect. Sixty-one percent were content with the treatment, and 74% would recommend it to others with COPD. During interview, patients reported on their need and openness to new and safe treatment options. Using the Global Evaluation of Treatment Effectiveness (GETE) tool, 30% reported on marked improvements following dupilumab. Treatment limitations were costs (48%) and repeated injections (21%).</p><p><strong>Conclusion: </strong>In this case-series, dupilumab was shown to be well tolerated and was associated with lower rates of exacerbations and improved symptoms. These outcomes were supported by patient reported outcome measurements.</p>","PeriodicalId":48818,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"20 ","pages":"2753-2760"},"PeriodicalIF":3.1,"publicationDate":"2025-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12336371/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144822992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identifying Eligibility for Specialist Intervention in COPD from UK Primary Care Data: A \"Treatable Traits\" Approach.","authors":"Thomas J C Ward, Catherine John, Alexander T Williams, Chiara Batini, Neil J Greening, Martin D Tobin, Michael C Steiner","doi":"10.2147/COPD.S502865","DOIUrl":"10.2147/COPD.S502865","url":null,"abstract":"<p><strong>Background: </strong>Specialist intervention in COPD is often reactive, resulting in inequalities in the provision of care. A proactive approach, in which individuals with modifiable disease are identified from primary care records, may help to tackle this inequality in access.</p><p><strong>Aim: </strong>To estimate the prevalence of \"treatable traits\" in COPD in a primary care research database and to assess health service usage.</p><p><strong>Methods: </strong>We performed a secondary analysis of individuals with either 1) a primary care diagnosis of COPD or 2) obstructive spirometry and history of ever smoking in a large observational study recruiting individuals aged 40-69 years old in Leicestershire, UK. Spirometry, height, weight and smoking history were collected prospectively and linked to individuals' primary care records. \"Treatable traits\" were identified from primary care records (frequent exacerbations, current smoking, low body mass index, respiratory failure, severe breathlessness, potential suitability for lung volume reduction or psychological comorbidity). Differences in demographics and health usage between those with and without \"treatable traits\" were assessed.</p><p><strong>Results: </strong>In total, of the 347 individuals with COPD, 186 had at least one \"treatable trait\". Compared to those without treatable traits, individuals with treatable traits were younger (61 vs 64 years, p<0.001), had more severe airflow obstruction (FEV₁ 86% vs 94% predicted, p=0.002), higher eosinophil count (0.32 vs 0.27 cells/μL, p=0.04) and were more socioeconomically deprived (UK Indices of Multiple Deprivation decile 4.3 vs 5.8, p<0.001). Individuals with treatable traits had a higher annual primary care health usage (47 vs 30 visits per year, p=0.001). Referrals rates to specialist respiratory services were low in both groups.</p><p><strong>Conclusion: </strong>Treatable traits are common in COPD and can be identified from routinely collected primary care data. Treatable traits are associated with younger age and greater deprivation. These individuals pose a significant burden to primary care yet are rarely referred to specialist respiratory services.</p>","PeriodicalId":48818,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"20 ","pages":"2761-2766"},"PeriodicalIF":3.1,"publicationDate":"2025-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12335837/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144818052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}